REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Exploring the Adherence Challenges and Influencing Factors of GLP-1 Receptor Agonists Among Patients With Overweight or Obesity
Back to Research Library
GLP-1 receptor agonistsliraglutidesemaglutidetirzepatide

Exploring the Adherence Challenges and Influencing Factors of GLP-1 Receptor Agonists Among Patients With Overweight or Obesity

May 16, 2026
Share

Source Paper

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.

Rodriguez Patricia J et al.JAMA network open2025
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

Adherence Challenges to GLP-1 Receptor Agonists: Insights from a Large-Scale Retrospective Study

Published: May 16, 2026 | Source: JAMA network open (2025) | Category: GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide

Overview

A recent study published in the JAMA Network Open has shed light on the adherence challenges faced by patients using glucagon-like peptide-1 (GLP-1) receptor agonists for weight management. The research reveals that individuals without type 2 diabetes are more likely to discontinue their GLP-1 treatment compared to those with the condition, highlighting significant differences in patient adherence patterns.

Study Background

GLP-1 receptor agonists have become a cornerstone of obesity and diabetes management due to their effectiveness in weight loss and glycemic control. However, ensuring long-term adherence remains a critical challenge. Previous studies have noted varying levels of discontinuation rates but lacked detailed insights into the factors influencing these decisions among patients with overweight or obesity.

What the Research Found

The study analyzed data from 125,474 adults who started using GLP-1 receptor agonists (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023. Among these patients, 61% had type 2 diabetes. The research found that one-year discontinuation rates were significantly higher for those without type 2 diabetes (64.8%) compared to those with the condition (46.5%). Furthermore, weight loss was associated with lower risks of discontinuing treatment: a 1% reduction in weight from baseline correlated with a 3.1% and 3.3% decrease in discontinuation risk for patients with and without type 2 diabetes, respectively.

What This Means for Peptide Users

The findings suggest that adherence to GLP-1 receptor agonists is influenced by the presence of type 2 diabetes and weight loss outcomes. Patients without type 2 diabetes may face additional challenges in maintaining long-term treatment adherence due to factors such as perceived necessity or side effects like gastrointestinal issues, which can be mitigated through better patient education and support.

Limitations and Caveats

The retrospective nature of the study limits its ability to establish causality between variables. Additionally, reliance on electronic health records introduces potential biases related to data completeness and accuracy. These limitations underscore the need for further research using prospective designs to confirm these findings and explore additional influencing factors such as patient education levels and socioeconomic status.

How This Compares to Previous Research

Previous studies have also noted higher discontinuation rates among patients with overweight or obesity, but this study provides a more nuanced understanding by stratifying results based on the presence of type 2 diabetes. The association between weight loss and adherence aligns with earlier research that emphasized the importance of treatment efficacy in sustaining patient engagement.

Our Analysis

PeptideVault views this study as an important contribution to our understanding of GLP-1 receptor agonist adherence, particularly among patients without type 2 diabetes. While it highlights critical areas for improvement, such as addressing gastrointestinal side effects and enhancing patient education, the retrospective design limits definitive conclusions about causality.

Key Takeaways

  • Higher Discontinuation Rates: Patients without type 2 diabetes have higher discontinuation rates compared to those with the condition.
  • Weight Loss Impact: Weight loss is associated with improved adherence to GLP-1 receptor agonists.
  • Gastrointestinal Side Effects: These are significant factors in treatment discontinuation, underscoring the need for better management strategies.

Original Source

Citation: Rodriguez Patricia J, Zhang Vincent, Gratzl Samuel et al. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.. JAMA network open. DOI: 10.1001/jamanetworkopen.2024.57349

Access: https://pubmed.ncbi.nlm.nih.gov/39888616/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the Peptide Contacts research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

Related Research

Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.

tirzepatideGIP receptor agonistGLP-1 receptor agonist

Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.

semaglutideGLP-1 receptor agonist

Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.

liraglutideatrial natriuretic peptiderelaxin mimetics

Comments

Sign in to join the discussion

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.